Profile: Pluristem Life Systems
BHI Company Directory Profile
Pluristem Life Systems
MATAM Advanced Technology Park
# 20
Haifa 31905, Israel
Tel : 972-4-850-1080
Fax : 972-4-850-1085
info@pluristem.com
Pluristem Life Systems, Inc. (OTCBB: PLRS) is a biotechnology Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem’s products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company’s proprietary PluriX™ 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
Pluristem's PluriX™ 3D Bioreactor
Pluristem's patented (US 6,911,201) bioreactor, trademarked PluriX™, promotes the rapid expansion of stem cells without the use of growth factors, cytokines and other exogenous materials in emulating the bone marrow microenvironment. Pluristem’s expansion technology also allows for the natural delay in the stem cell’s tendency to differentiate into dedicated tissue.
For decades, scientists have attempted to "grow" stem cells outside of the human body in culture in an attempt to increase the number of these cells for transplantation. The challenge of this undertaking lies in overcoming the stem cells' predisposition to differentiate into dedicated cells. Stem cells tend to produce other cells with limited repopulating properties when grown in culture rather than to replicate and regenerate additional stem cells. Current stem cell expansion techniques are complicated by the diverse mixture of differentiated cells generated in stem cell cultures. Existing scientific methods currently in use to increase the number of stem cells include culturing the cells on two dimensional stromal layers and growing them in the presence of cytokines, growth factors and other exogenous chemicals. To the best of our knowledge, none of these existing methods that attempt to grow stem cells outside of patients' bodies are able to prevent differentiation of these cells while promoting their proliferation.
Pluristem’s PluriX™ 3D bioreactor technology is a system of stromal cell cultures and substrates that create an artificially induced physiological environment where stem cells can grow and reproduce outside of the human body. The system mimics the environment existing in human bone marrow where stem cells reproduce naturally. Additionally, because the size and scale of the PluriX™ 3D bioreactor can be made larger than human bone marrow, the stem cell growth can be greatly expanded. We believe the three dimensional PluriX™ bioreactor system has the potential to be involved in the expansion of stem cells in proportions that will be enough for transplants without promoting differentiation.
The general idea is to cause self-renewal of early stage stem cells and prevent them from differentiating through use of the PluriX™ Bioreactor system. This system is in direct contrast to standard teflon bags or culture flasks, which cannot promote stem cells self-renewal and prevent their differentiation. In the PluriX™ Bioreactor system, stem cells are influenced by contact with the surrounding environment, made up of stromal cell cultures and substrates. Therefore, by keeping the stem cells in the closed environment of the PluriX™ Bioreactor system, the stem cells maintain their original form, which means that they can proliferate without differentiating.
Pluristem's PLacetal eXpanded (PLX) Cells
Pluristem is currently designing and developing the PluriX™ Bioreactor system to perform the controlled expansion of mesenchymal stem cells (MSCs) that are derived from the placenta. These PLacental eXpanded (PLX) cells have been found to possess favorable characteristics that Pluristem believes will allow these cells to be used in the treatment of a variety of disorders. These characteristics include the PLX cell’s ability to be not only immune privileged but immuno-suppressive; favorable immunological qualities that should help prevent and even treat the rejection reactions that so often occur with transplantation. Additionally, Pluristem has evidence to suggest that PLX cell are totipotent and able to evolve into a variety of tissue types including bone, cartilage, muscle, tendon, ligament and the supporting environment for hematopoietic stem cells (HSCs). Therefore, Pluristem believes their proprietary PLX cells may be useful in a spectrum of diseases including degenerative, malignant, immunological and hematological disorders.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
Pluristem Life SystemsMATAM Advanced Technology Park
# 20
Haifa 31905, Israel
Tel : 972-4-850-1080
Fax : 972-4-850-1085
info@pluristem.com
Pluristem Life Systems, Inc. (OTCBB: PLRS) is a biotechnology Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem’s products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company’s proprietary PluriX™ 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
Pluristem's PluriX™ 3D Bioreactor
Pluristem's patented (US 6,911,201) bioreactor, trademarked PluriX™, promotes the rapid expansion of stem cells without the use of growth factors, cytokines and other exogenous materials in emulating the bone marrow microenvironment. Pluristem’s expansion technology also allows for the natural delay in the stem cell’s tendency to differentiate into dedicated tissue.
For decades, scientists have attempted to "grow" stem cells outside of the human body in culture in an attempt to increase the number of these cells for transplantation. The challenge of this undertaking lies in overcoming the stem cells' predisposition to differentiate into dedicated cells. Stem cells tend to produce other cells with limited repopulating properties when grown in culture rather than to replicate and regenerate additional stem cells. Current stem cell expansion techniques are complicated by the diverse mixture of differentiated cells generated in stem cell cultures. Existing scientific methods currently in use to increase the number of stem cells include culturing the cells on two dimensional stromal layers and growing them in the presence of cytokines, growth factors and other exogenous chemicals. To the best of our knowledge, none of these existing methods that attempt to grow stem cells outside of patients' bodies are able to prevent differentiation of these cells while promoting their proliferation.
Pluristem’s PluriX™ 3D bioreactor technology is a system of stromal cell cultures and substrates that create an artificially induced physiological environment where stem cells can grow and reproduce outside of the human body. The system mimics the environment existing in human bone marrow where stem cells reproduce naturally. Additionally, because the size and scale of the PluriX™ 3D bioreactor can be made larger than human bone marrow, the stem cell growth can be greatly expanded. We believe the three dimensional PluriX™ bioreactor system has the potential to be involved in the expansion of stem cells in proportions that will be enough for transplants without promoting differentiation.
The general idea is to cause self-renewal of early stage stem cells and prevent them from differentiating through use of the PluriX™ Bioreactor system. This system is in direct contrast to standard teflon bags or culture flasks, which cannot promote stem cells self-renewal and prevent their differentiation. In the PluriX™ Bioreactor system, stem cells are influenced by contact with the surrounding environment, made up of stromal cell cultures and substrates. Therefore, by keeping the stem cells in the closed environment of the PluriX™ Bioreactor system, the stem cells maintain their original form, which means that they can proliferate without differentiating.
Pluristem's PLacetal eXpanded (PLX) Cells
Pluristem is currently designing and developing the PluriX™ Bioreactor system to perform the controlled expansion of mesenchymal stem cells (MSCs) that are derived from the placenta. These PLacental eXpanded (PLX) cells have been found to possess favorable characteristics that Pluristem believes will allow these cells to be used in the treatment of a variety of disorders. These characteristics include the PLX cell’s ability to be not only immune privileged but immuno-suppressive; favorable immunological qualities that should help prevent and even treat the rejection reactions that so often occur with transplantation. Additionally, Pluristem has evidence to suggest that PLX cell are totipotent and able to evolve into a variety of tissue types including bone, cartilage, muscle, tendon, ligament and the supporting environment for hematopoietic stem cells (HSCs). Therefore, Pluristem believes their proprietary PLX cells may be useful in a spectrum of diseases including degenerative, malignant, immunological and hematological disorders.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
posted by Nico at
5:02 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home